Trials / Unknown
UnknownNCT05053295
Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer
An Open-label, Single-arm, Single-center, Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo®) in Subjects With Advanced or Recurrent Gastric Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | autologous activated T lymphocyte | Drug: Immuncell-LC IV Drug: Nivolumab (Opdivo®) IV |
Timeline
- Start date
- 2021-07-02
- Primary completion
- 2023-07-01
- Completion
- 2023-09-30
- First posted
- 2021-09-22
- Last updated
- 2021-09-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05053295. Inclusion in this directory is not an endorsement.